Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration

Behavioural Brain Research

Volumn 302, Issue , 2016, Pages 279-290

  Krishna, Saritha ^a   Dodd, Celia A ^a,b   Filipov, Nikolay M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b FORT VALLEY STATE UNIVERSITY   (United States)

Author keywords

Depressive like behavior; Inflammation; Lipopolysaccharide; Splenic serotonin

Indexed keywords

LIPOPOLYSACCHARIDE; MONOAMINE; SEROTONIN; BIOGENIC AMINE; CYTOKINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BODY WEIGHT; CHRONIC INFLAMMATION; COGNITION; CONTROLLED STUDY; FOOD INTAKE; FORCED SWIM TEST; GRIP STRENGTH; HOMEOSTASIS; HYPERACTIVITY; LOCOMOTION; MALE; MICROGLIA; MOUSE; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD TEST; ORGAN WEIGHT; PRIORITY JOURNAL; ANIMAL; BRAIN; CHEMICALLY INDUCED; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EATING; ETIOLOGY; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MUSCLE STRENGTH; ORGAN SIZE; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SPLEEN; SWIMMING; TIME FACTOR;

ANIMALS; ANXIETY; BIOGENIC MONOAMINES; BODY WEIGHT; BRAIN; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; EATING; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; INFLAMMATION; LIPOPOLYSACCHARIDES; LOCOMOTION; MALE; MICE; MUSCLE STRENGTH; ORGAN SIZE; PSYCHOMOTOR PERFORMANCE; SPLEEN; SWIMMING; TIME FACTORS;

EID: 84955559093     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.01.038     Document Type: Article

References (96)

1. Di Filippo M., Chiasserini D., Gardoni F., Viviani B., Tozzi A., Giampa C., et al. Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol. Dis. 2013, 52:229-236.
2. Machado A., Herrera A.J., Venero J.L., Santiago M., De Pablos R.M., Villaran R.F., et al. Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis. 2011, 2011:393769.
3. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J. Neuroimmunol. 2006, 172:38-58.
4. Ziemssen T., Kern S. Psychoneuroimmunology-cross-talk between the immune and nervous systems. J. Neurol. 2007, 254(Suppl. 2):II8-11.
5. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 2002, 112:7-11.
6. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005, 25:9275-9284.
7. Ferrari C.C., Tarelli R. Parkinson's disease and systemic inflammation. Parkinsons Dis. 2011, 2011:436813.
8. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 2004, 18:407-413.
9. Puntener U., Booth S.G., Perry V.H., Teeling J.L. Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J. Neuroinflammation 2012, 9:146.
10. Dunn A.J. Effects of cytokines and infections on brain neurochemistry. Clin. Neurosci. Res. 2006, 6:52-68.
11. MohanKumar S.M., MohanKumar P.S., Quadri S.K. Lipopolysaccharide-induced changes in monoamines in specific areas of the brain: blockade by interleukin-1 receptor antagonist. Brain Res. 1999, 824:232-237.
12. Lacosta S., Merali Z., Anisman H. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Res. 1999, 818:291-303.
13. Molina-Holgado F., Guaza C. Endotoxin administration induced differential neurochemical activation of the rat brain stem nuclei. Brain Res. Bull. 1996, 40:151-156.
14. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N. Y. Acad. Sci. 2001, 933:222-234.
15. Maes M., Berk M., Goehler L., Song C., Anderson G., Galecki P., et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012, 10:66.
16. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:15.
17. Sah S.P., Tirkey N., Kuhad A., Chopra K. Effect of quercetin on lipopolysaccharide induced-sickness behavior and oxidative stress in rats. Indian J. Pharmacol. 2011, 43:192-196.
18. Swiergiel A.H., Dunn A.J. Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacol. Biochem. Behav. 2007, 86:651-659.
19. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
20. Fu X., Zunich S.M., O'Connor J.C., Kavelaars A., Dantzer R., Kelley K.W. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J. Neuroinflammation 2010, 7:43.
21. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
22. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
23. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
24. Steptoe A., Hamer M., Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 2007, 21:901-912.
25. Williams E.D., Steptoe A. The role of depression in the etiology of acute coronary syndrome. Curr. Psychiatry Rep. 2007, 9:486-492.
26. Adzovic L., Lynn A.E., D'Angelo H.M., Crockett A.M., Kaercher R.M., Royer S.E., et al. Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J. Neuroinflammation 2015, 12:63.
27. Elgarf A.S., Aboul-Fotouh S., Abd-Alkhalek H.A., El Tabbal M., Hassan A.N., Kassim S.K., et al. Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol. Biochem. Behav. 2014, 126:152-162.
28. Pan Y., Lin W., Wang W., Qi X., Wang D., Tang M. The effects of central pro-and anti-inflammatory immune challenges on depressive-like behavior induced by chronic forced swim stress in rats. Behav. Brain Res. 2013, 247:232-240.
29. Hwang Y.K., Jinhua M., Choi B.R., Cui C.A., Jeon W.K., Kim H., et al. Effects of Scutellaria baicalensis on chronic cerebral hypoperfusion-induced memory impairments and chronic lipopolysaccharide infusion-induced memory impairments. J. Ethnopharmacol. 2011, 137:681-689.
30. Franciosi S., Ryu J.K., Shim Y., Hill A., Connolly C., Hayden M.R., et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012, 45:438-449.
31. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 2008, 28:10825-10834.
32. Heneka M.T., Kummer M.P., Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014, 14:463-477.
33. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81:1285-1297.
34. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
35. Belarbi K., Arellano C., Ferguson R., Jopson T., Rosi S. Chronic neuroinflammation impacts the recruitment of adult-born neurons into behaviorally relevant hippocampal networks. Brain Behav. Immun. 2012, 26:18-23.
36. Rosi S., Ramirez-Amaya V., Hauss-Wegrzyniak B., Wenk G.L. Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors. J. Neuroinflammation 2004, 1:12.
37. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
38. Morrison B.E., Marcondes M.C., Nomura D.K., Sanchez-Alavez M., Sanchez-Gonzalez A., Saar I., et al. Cutting edge: IL-13Ralpha1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J. Immunol. 2012, 189:5498-5502.
39. You Z., Luo C., Zhang W., Chen Y., He J., Zhao Q., et al. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav. Brain Res. 2011, 225:135-141.
40. Walker R.F., Codd E.E. Neuroimmunomodulatory interactions of norepinephrine and serotonin. J. Neuroimmunol. 1985, 10:41-58.
41. Vriend C.Y., Zuo L., Dyck D.G., Nance D.M., Greenberg A.H. Central administration of interleukin-1 beta increases norepinephrine turnover in the spleen. Brain Res. Bull. 1993, 31:39-42.
42. Terao A., Kitamura H., Asano A., Kobayashi M., Saito M. Roles of prostaglandins D2 and E2 in interleukin-1-induced activation of norepinephrine turnover in the brain and peripheral organs of rats. J. Neurochem. 1995, 65:2742-2747.
43. Carroll I.M., Maharshak N. Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. World J. Gastroenterol. 2013, 19:7531-7543.
44. Young D., Hussell T., Dougan G. Chronic bacterial infections: living with unwanted guests. Nat. Immunol. 2002, 3:1026-1032.
45. Kubera M., Curzytek K., Duda W., Leskiewicz M., Basta-Kaim A., Budziszewska B., et al. A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain Behav. Immun. 2013, 31:96-104.
46. Krishna S., Dodd C.A., Hekmatyar S.K., Filipov N.M. Brain deposition and neurotoxicity of manganese in adult mice exposed via the drinking water. Arch. Toxicol. 2014, 88:47-64.
47. Lin Z., Dodd C.A., Filipov N.M. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice. Neurotoxicol. Teratol. 2013, 39:26-35.
48. Crawley J.N. What's wrong with my mouse?. Behavioral Phenotyping of Transgenic and Knockout Mice 2002, 53-55. John Wiley & Sons, Inc., New York.
49. Mutseura M., Tagwireyi D., Gadaga L.L. Pre-treatment of BALB/c mice with a centrally acting serotonin antagonist (cyproheptadine) reduces mortality from Boophone disticha poisoning. Clin. Toxicol. (Phila.) 2013, 51:16-22.
50. Paylor R., Spencer C.M., Yuva-Paylor L.A., Pieke-Dahl S. The use of behavioral test batteries, II: effect of test interval. Physiol. Behav. 2006, 87:95-102.
51. Bailey K.R., Crawley J.N. Methods of Behavior Analysis in Neuroscience 2009, CRC Press, Florida. 2nd ed.
52. Staropoli J.F., Haliw L., Biswas S., Garrett L., Holter S.M., Becker L., et al. Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One 2012, 7:e38310.
53. Royl G., Balkaya M., Lehmann S., Lehnardt S., Stohlmann K., Lindauer U., et al. Effects of the PDE5-inhibitor vardenafil in a mouse stroke model. Brain Res. 2009, 1265:148-157.
54. Coban A., Filipov N.M. Dopaminergic toxicity associated with oral exposure to the herbicide atrazine in juvenile male C57BL/6 mice. J. Neurochem. 2007, 100:1177-1187.
55. Dodd C.A., Filipov N.M. Manganese potentiates LPS-induced heme-oxygenase 1 in microglia but not dopaminergic cells: role in controlling microglial hydrogen peroxide and inflammatory cytokine output. Neurotoxicology 2011, 32:683-692.
56. Ku I.A., Imboden J.B., Hsue P.Y., Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ. J. 2009, 73:977-985.
57. Ohl K., Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 2011:432595.
58. Maier S.F. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav. Immun. 2003, 17:69-85.
59. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., et al. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med. 2013, 11:200.
60. MacDonald L., Hazi A., Paolini A.G., Kent S. Calorie restriction dose-dependently abates lipopolysaccharide-induced fever, sickness behavior, and circulating interleukin-6 while increasing corticosterone. Brain Behav. Immun. 2014, 40:18-26.
61. Hauser W., Janke K.H., Klump B., Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm. Bowel Dis. 2011, 17:621-632.
62. Hoyo-Becerra C., Schlaak J.F., Hermann D.M. Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation. Brain Behav. Immun. 2014, 42:222-231.
63. Krishnadas R., Cavanagh J. Depression: an inflammatory illness. J. Neurol. Neurosurg. Psychiatry 2012, 83:495-502.
64. Janssen H.L., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 1994, 21:241-243.
65. Koseki K., Nakano M., Takaiwa M., Kamata T., Yosida J. Suicidal attempts in three postoperative patients with renal cancer after alpha interferon withdrawal. Nihon Hinyokika Gakkai Zasshi 2000, 91:29-32.
66. Rifflet H., Vuillemin E., Oberti F., Duverger P., Laine P., Garre J.B., et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol. Clin. Biol. 1998, 22:353-357.
67. Pelloux Y., Hagues G., Costentin J., Duterte-Boucher D. Helplessness in the tail suspension test is associated with an increase in ethanol intake and its rewarding effect in female mice. Alcohol Clin. Exp. Res. 2005, 29:378-388.
68. Sclafani A., Hertwig H., Vigorito M., Feigin M.B. Sex differences in polysaccharide and sugar preferences in rats. Neurosci. Biobehav. Rev. 1987, 11:241-251.
69. Lorton D., Lubahn C., Felten S.Y., Bellinger D. Norepinephrine content in primary and secondary lymphoid organs is altered in rats with adjuvant-induced arthritis. Mech. Ageing Dev. 1997, 94:145-163.
70. Assinger A. Platelets and infection-an emerging role of platelets in viral infection. Front. Immunol. 2014, 5:649.
71. Cleare A.J. Reduced whole blood serotonin in major depression. Depress. Anxiety 1997, 5:108-111.
72. Mann J.J., McBride P.A., Anderson G.M., Mieczkowski T.A. Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. Biol. Psychiatry 1992, 32:243-257.
73. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001, 105:45-55.
74. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 463:3-33.
75. Bolivar V.J. Intrasession and intersession habituation in mice: from inbred strain variability to linkage analysis. Neurobiol. Learn. Mem. 2009, 92:206-214.
76. Crawley J.N. What's wrong with my mouse. Behavioral Phenotyping of Transgenic and Knockout Mice 2007, John Wiley & Sons, New Jersey. second ed.
77. Jacewicz M., Czapski G.A., Katkowska I., Strosznajder R.P. Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol. 2009, 47:321-328.
78. Bossu P., Cutuli D., Palladino I., Caporali P., Angelucci F., Laricchiuta D., et al. A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-alpha and IL-18. J. Neuroinflammation 2012, 9:101.
79. Song J.H., Lee J.W., Shim B., Lee C.Y., Choi S., Kang C., et al. Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. Molecules 2013, 18:15788-15803.
80. Chefer V.I., Thompson A.C., Zapata A., Shippenberg T.S. Overview of brain microdialysis. Curr. Protoc. Neurosci. 2009, Chapter 7: Unit7 1.
81. Liu M., Bing G. Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011, 2011:327089.
82. Moreau J.L. Simulating the anhedonia symptom of depression in animals. Dialogues Clin. Neurosci. 2002, 4:351-360.
83. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 1999, 461:75-81.
84. Anisman H., Kokkinidis L., Borowski T., Merali Z. Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res. 1998, 779:177-187.
85. Drevets W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry 2000, 48:813-829.
86. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res. 2009, 201:239-243.
87. Savitz J., Frank M.B., Victor T., Bebak M., Marino J.H., Bellgowan P.S., et al. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav. Immun. 2013, 31:161-171.
88. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36:764-785.
89. Kwant A., Sakic B. Behavioral effects of infection with interferon-gamma adenovector. Behav. Brain Res. 2004, 151:73-82.
90. Cavaillon J.M. Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 2006, 10:233.
91. Chen R., Zhou H., Beltran J., Malellari L., Chang S.L. Differential expression of cytokines in the brain and serum during endotoxin tolerance. J. Neuroimmunol. 2005, 163:53-72.
92. Lehner M.D., Hartung T. Endotoxin tolerance-mechanisms and beneficial effects in bacterial infection. Rev. Physiol. Biochem. Pharmacol. 2002, 144:95-141.
93. Banasikowski T.J., Cloutier C.J., Ossenkopp K.P., Kavaliers M. Repeated exposure of male mice to low doses of lipopolysaccharide: dose and time dependent development of behavioral sensitization and tolerance in an automated light-dark anxiety test. Behav. Brain Res. 2015, 286:241-248.
94. Engeland C.G., Nielsen D.V., Kavaliers M., Ossenkopp K.P. Locomotor activity changes following lipopolysaccharide treatment in mice: a multivariate assessment of behavioral tolerance. Physiol. Behav. 2001, 72:481-491.
95. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7:1107-1114.
96. Owen B.M., Eccleston D., Ferrier I.N., Young A.H. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr. Scand. 2001, 103:226-228.